Home › Blood Cancers › NCT06469307
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RecruitingHealthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
CAB Participant Inclusion Criteria: * Age 18 or older * English speaking * Ability to understand and willingness to provide oral consent * DFCI patient who are in remission from a blood cancer \>1 year will be preferred. CAB Participant Exclusion Criteria: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers \<18 years old) * Prisoners. * Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1 * Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed. * Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews. Investigator Participant Inclusion Criteria: * Age 18 older * English Speaking * Site or Principal investigator * Not a member of the research team
About the study
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
What is being tested
- DIVERSE Review Process (other)
Sponsor: Dana-Farber Cancer Institute · Participants: 40 · Started: Dec 9, 2024
Contact the study team
- Andrew Hantel, MD · Phone: 617-582-9394
- Oldy S Bejarano, MPH · Phone: 857-215-2365
Official record on ClinicalTrials.gov — NCT06469307
Locations in the U.S.
| Massachusetts | Dana-Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.